Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301472 | 1.00 | KMO (0.57) | KMOGPBAR1HSD17B1HSD17B2MAP4K4 | |
| SCHEMBL31301328 | 0.95 | KMO (0.62) | KMOGPBAR1MAP4K4MEN1KMT2A | |
| SCHEMBL31301465 | 0.94 | HSD17B1 (0.49) | KMOGPBAR1HSD17B1HSD17B2MEN1 | |
| SCHEMBL31301337 | 0.88 | KMO (0.54) | KMOGPBAR1MAP4K4MEN1KMT2A | |
| SCHEMBL31301385 | 0.87 | KMO (0.53) | KMOGPBAR1MAP4K4MEN1KMT2A | |
| SCHEMBL31301462 | 0.86 | GPBAR1 (0.53) | KMOGPBAR1MAP4K4MEN1KMT2A | |
| SCHEMBL31301429 | 0.80 | GPBAR1 (0.51) | KMOGPBAR1HSD17B1HSD17B2MAP4K4 | |
| SCHEMBL31301440 | 0.79 | GPBAR1 (0.55) | GPBAR1HSD17B1HSD17B2MAPTSMN1; SMN2 | |
| SCHEMBL31301282 | 0.78 | GPBAR1 (0.51) | GPBAR1HSD17B1HSD17B2MAP4K4PIK3CG | |
| SCHEMBL31301452 | 0.77 | GPBAR1 (0.53) | KMOGPBAR1HSD17B1HSD17B2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | KMO 2781/4885GPBAR1 803/4885HSD17B1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.